| scholarly article | Q13442814 |
| P50 | author | Brandon B Holmes | Q85308707 |
| P2093 | author name string | Tao Shen | |
| Holly B Kordasiewicz | |||
| Marc I Diamond | |||
| Eric E Swayze | |||
| Guo Chen | |||
| Hien Tran | |||
| Sarah L DeVos | |||
| Brandon Nichols | |||
| Rebecca L Miller | |||
| Timothy M Miller | |||
| C Frank Bennett | |||
| Kathleen M Schoch | |||
| Tom A Zanardi | |||
| Carey S Kebodeaux | |||
| Amy J Wegener | |||
| P2860 | cites work | RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention | Q24562489 |
| Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds | Q24630644 | ||
| Mechanisms of protein seeding in neurodegenerative diseases | Q26994962 | ||
| Antisense oligonucleotides: treating neurodegeneration at the level of RNA | Q27007056 | ||
| Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits | Q27314989 | ||
| Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy | Q27316185 | ||
| Does neuroinflammation fan the flame in neurodegenerative diseases? | Q27498993 | ||
| Neuropathological stageing of Alzheimer-related changes | Q27860862 | ||
| Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model | Q28115206 | ||
| Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models | Q28119018 | ||
| The MAPT H1 haplotype is associated with tangle-predominant dementia | Q28271237 | ||
| Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice | Q28484481 | ||
| Tau reduction prevents Abeta-induced defects in axonal transport. | Q28585545 | ||
| Trans-synaptic spread of tau pathology in vivo | Q28732288 | ||
| Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy | Q29417026 | ||
| GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease | Q29417137 | ||
| Tau suppression in a neurodegenerative mouse model improves memory function | Q29615831 | ||
| Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model | Q29617937 | ||
| Propagation of tau pathology in a model of early Alzheimer's disease | Q29620203 | ||
| P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating | Q30475074 | ||
| Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. | Q30513293 | ||
| Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-β | Q30539255 | ||
| Seizure resistance without parkinsonism in aged mice after tau reduction | Q30587394 | ||
| Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial | Q34031302 | ||
| Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice | Q34102829 | ||
| Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy | Q34168139 | ||
| Alzheimer's disease: cell-specific pathology isolates the hippocampal formation | Q34261572 | ||
| Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. | Q34283652 | ||
| Proteopathic tau seeding predicts tauopathy in vivo. | Q34383788 | ||
| Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling | Q34506149 | ||
| Antisense oligonucleotide therapy for neurodegenerative disease. | Q34830633 | ||
| Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice | Q35496991 | ||
| Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus | Q35963497 | ||
| Assessing burrowing, nest construction, and hoarding in mice | Q36015466 | ||
| Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis | Q36073366 | ||
| No Overt Deficits in Aged Tau-Deficient C57Bl/6.Mapttm1(EGFP)Kit GFP Knockin Mice | Q36162472 | ||
| Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain | Q36169754 | ||
| Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity | Q36394952 | ||
| Sensitive Detection of Proteopathic Seeding Activity with FRET Flow Cytometry | Q36408405 | ||
| Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature | Q36575903 | ||
| Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy | Q36661721 | ||
| Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice | Q36681296 | ||
| Direct intraventricular delivery of drugs to the rodent central nervous system | Q36921774 | ||
| An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study | Q37015657 | ||
| Antisense reduction of tau in adult mice protects against seizures | Q37058143 | ||
| Reversal of neurofibrillary tangles and tau-associated phenotype in the rTgTauEC model of early Alzheimer's disease | Q37093852 | ||
| Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model | Q37292146 | ||
| Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration | Q37340843 | ||
| Neuronal activity regulates extracellular tau in vivo | Q37630201 | ||
| Frontotemporal dementia: implications for understanding Alzheimer disease | Q37987142 | ||
| Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases | Q38289739 | ||
| Neurodegenerative disease in 2015: Targeting tauopathies for therapeutic translation | Q38705770 | ||
| Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients | Q41046533 | ||
| Distinct tau prion strains propagate in cells and mice and define different tauopathies | Q41904960 | ||
| Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. | Q41955482 | ||
| Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression | Q43806330 | ||
| Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. | Q45810537 | ||
| Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease | Q46252763 | ||
| Impairment of nesting behaviour in 3xTg-AD mice. | Q46767084 | ||
| Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice | Q48166478 | ||
| Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice | Q48289964 | ||
| Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice | Q48650483 | ||
| Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. | Q48686425 | ||
| Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. | Q50782460 | ||
| Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. | Q50856591 | ||
| Inflammation and Alzheimer's disease | Q82323473 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 374 | |
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Science Translational Medicine | Q1573955 |
| P1476 | title | Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy | |
| P478 | volume | 9 |
| Q55026197 | 2017 Year in Review and Message from the Editors to Our Reviewers. |
| Q39270980 | A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies |
| Q49913378 | A role for tau in learning, memory and synaptic plasticity |
| Q55364537 | A silver lining for 24-hydroxycholesterol in Alzheimer's disease: The involvement of the neuroprotective enzyme sirtuin 1. |
| Q64245708 | A walk through tau therapeutic strategies |
| Q38666247 | Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches |
| Q90351471 | Alzheimer Disease: An Update on Pathobiology and Treatment Strategies |
| Q89386640 | Alzheimer disease: Antisense oligonucleotide reverses tau pathology |
| Q89962342 | Alzheimer's disease: phenotypic approaches using disease models and the targeting of tau protein |
| Q60530541 | Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease -conformist, nonconformist, and realistic prospects for AD pathogenesis |
| Q46240783 | Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies. |
| Q91526804 | Amyloid-β-independent regulators of tau pathology in Alzheimer disease |
| Q92232193 | An update on genetic frontotemporal dementia |
| Q39391538 | Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases |
| Q58617295 | Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles |
| Q90236625 | Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models |
| Q92285830 | Antisense oligonucleotides extend survival of prion-infected mice |
| Q55018458 | Antisense oligonucleotides in neurological disorders. |
| Q64096491 | Antisense oligonucleotides: A primer |
| Q47344432 | Antisense oligonucleotides: the next frontier for treatment of neurological disorders |
| Q50199042 | Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects |
| Q90591149 | Development of disease-modifying drugs for frontotemporal dementia spectrum disorders |
| Q91707000 | Dreaming of a New World Where Alzheimer's Is a Treatable Disorder |
| Q47284348 | Editorial: Pathogenic templating proteins in Neurodegenerative Disease. |
| Q48328560 | Enzymatic Synthesis of 7',5'-Bicyclo-DNA Oligonucleotides |
| Q95933928 | Evaluating drug targets through human loss-of-function genetic variation |
| Q42288828 | Expression of Tau Pathology-Related Proteins in Different Brain Regions: A Molecular Basis of Tau Pathogenesis |
| Q91938470 | Gene Therapy Tools for Brain Diseases |
| Q42371261 | Gene suppression approaches to neurodegeneration |
| Q93186032 | Identification of an ERK Inhibitor as a Therapeutic Drug Against Tau Aggregation in a New Cell-Based Assay |
| Q89459080 | MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways |
| Q91637583 | MicroRNAs in Alzheimer's Disease: Diagnostic Markers or Therapeutic Agents? |
| Q50532320 | Murine knockin model for progranulin-deficient frontotemporal dementia with nonsense-mediated mRNA decay. |
| Q64819927 | Neurotheranostics as personalized medicines |
| Q47880484 | Noncoding RNAs in neurodegeneration |
| Q54979137 | Novel Key Players in the Development of Tau Neuropathology: Focus on the 5-Lipoxygenase. |
| Q89262117 | Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy |
| Q51737325 | Oligonucleotide therapeutics in neurodegenerative diseases. |
| Q48288187 | Oligonucleotide therapies for disorders of the nervous system |
| Q59807147 | Polysaccharide Attenuates Tau Hyperphosphorylation and Cognitive Impairments in hTau Infected Mice |
| Q89054486 | Prion-like mechanisms in Alzheimer disease |
| Q39338832 | Propagation of Tau aggregates |
| Q90625138 | Protein production is an early biomarker for RNA-targeted therapies |
| Q90657221 | Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective |
| Q58027500 | Rodent models for Alzheimer disease |
| Q53699381 | Sequestration of synaptic proteins by alpha-synuclein aggregates leading to neurotoxicity is inhibited by small peptide. |
| Q64088424 | Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved |
| Q92535308 | Subregional Density of Neurons, Neurofibrillary Tangles and Amyloid Plaques in the Hippocampus of Patients With Alzheimer's Disease |
| Q53398002 | Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain. |
| Q33740999 | TDP-43 suppresses tau expression via promoting its mRNA instability |
| Q64054848 | Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models |
| Q57215461 | Tau Kinetics in Neurons and the Human Central Nervous System |
| Q88588446 | Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo |
| Q39151589 | The prion model for progression and diversity of neurodegenerative diseases |
| Q58725042 | The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer's disease |
| Q89470931 | Therapeutic approaches targeting Apolipoprotein E function in Alzheimer's disease |
| Q90559209 | Towards a treatment for genetic prion disease: trials and biomarkers |
| Q92775462 | Uses for humanised mouse models in precision medicine for neurodegenerative disease |
| Q89794613 | [Gene-specific treatment approaches in Alzheimer's disease and other tauopathies] |
| Q44893565 | α-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice |
Search more.